PE20200859A1 - Combinacion farmaceutica que comprende regonafenib y nivolumab como anticancerigeno - Google Patents

Combinacion farmaceutica que comprende regonafenib y nivolumab como anticancerigeno

Info

Publication number
PE20200859A1
PE20200859A1 PE2019002499A PE2019002499A PE20200859A1 PE 20200859 A1 PE20200859 A1 PE 20200859A1 PE 2019002499 A PE2019002499 A PE 2019002499A PE 2019002499 A PE2019002499 A PE 2019002499A PE 20200859 A1 PE20200859 A1 PE 20200859A1
Authority
PE
Peru
Prior art keywords
nivolumab
antibody
pharmaceutical combination
regonafenib
anticancer agent
Prior art date
Application number
PE2019002499A
Other languages
English (en)
Spanish (es)
Inventor
Sabine Hoff
Lars Rose
Dieter Zopf
Fabian Kiessling
Wiltrud Lederle
Dennis Doleschel
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of PE20200859A1 publication Critical patent/PE20200859A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
PE2019002499A 2017-06-02 2018-05-25 Combinacion farmaceutica que comprende regonafenib y nivolumab como anticancerigeno PE20200859A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17174169 2017-06-02
PCT/EP2018/063785 WO2018219807A1 (en) 2017-06-02 2018-05-25 Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer

Publications (1)

Publication Number Publication Date
PE20200859A1 true PE20200859A1 (es) 2020-08-25

Family

ID=58992733

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2024001939A PE20242220A1 (es) 2017-06-02 2018-05-25 Combinacion de regonafenib e inhibidores de pd-1/pd-l1(2) para el tratamiento contra el cancer
PE2019002499A PE20200859A1 (es) 2017-06-02 2018-05-25 Combinacion farmaceutica que comprende regonafenib y nivolumab como anticancerigeno

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2024001939A PE20242220A1 (es) 2017-06-02 2018-05-25 Combinacion de regonafenib e inhibidores de pd-1/pd-l1(2) para el tratamiento contra el cancer

Country Status (22)

Country Link
US (4) US11951166B2 (enExample)
EP (2) EP4342542A3 (enExample)
JP (3) JP7303122B2 (enExample)
KR (2) KR102843438B1 (enExample)
CN (3) CN110662540B (enExample)
AU (2) AU2018276273B2 (enExample)
BR (1) BR112019025478A8 (enExample)
CA (2) CA3065125C (enExample)
DK (1) DK3630112T3 (enExample)
ES (1) ES2978337T3 (enExample)
FI (1) FI3630112T3 (enExample)
HR (1) HRP20240551T1 (enExample)
HU (1) HUE066487T2 (enExample)
IL (2) IL317015A (enExample)
LT (1) LT3630112T (enExample)
MX (1) MX2023001721A (enExample)
PE (2) PE20242220A1 (enExample)
PL (1) PL3630112T3 (enExample)
PT (1) PT3630112T (enExample)
RS (1) RS65488B9 (enExample)
SI (1) SI3630112T1 (enExample)
WO (1) WO2018219807A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018219807A1 (en) * 2017-06-02 2018-12-06 Bayer Aktiengesellschaft Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer
CN111001004A (zh) * 2019-10-08 2020-04-14 广州医科大学附属第二医院 一种治疗肝癌的药物组合及其应用
WO2025117638A1 (en) * 2023-12-01 2025-06-05 Yale University Compositions and methods for treating cancer

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ544920A (en) 2003-07-23 2009-11-27 Bayer Healthcare Llc 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
KR20080074974A (ko) 2005-11-10 2008-08-13 바이엘 헬스케어 아게 당뇨병성 신경병증을 치료하기 위한 디아릴 우레아
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
UY35006A (es) * 2012-09-06 2014-03-31 Bayer Healthcare Llc Composición farmacéutica recubierta que contiene regorafenib
CA2885688C (en) 2012-09-25 2021-03-02 Bayer Pharma Aktiengesellschaft Combination of regorafenib and acetylsalicylic acid for treating cancer
JP5653489B1 (ja) 2013-07-24 2015-01-14 三菱エンジニアリングプラスチックス株式会社 薄肉光学部材用ポリカーボネート樹脂ペレット及びその製造方法
CN118286440A (zh) 2014-02-04 2024-07-05 辉瑞大药厂 用于治疗癌症的pd-1拮抗剂和vegfr抑制剂的组合
ES2808728T3 (es) 2014-02-21 2021-03-01 Idac Theranostics Inc Agente terapéutico para cáncer sólido
JP6626085B2 (ja) 2014-07-15 2019-12-25 ザ・ジョンズ・ホプキンス・ユニバーシティー 骨髄由来抑制細胞の抑制及び免疫チェックポイント阻害の方法
AR101210A1 (es) * 2014-07-15 2016-11-30 Genentech Inc Métodos de tratamiento de cáncer usando antagonistas de unión al eje pd-1 e inhibidores de mek
CN106794246B (zh) * 2014-08-08 2021-10-15 OncoQuest制药有限公司 肿瘤抗原特异性抗体和tlr3刺激以增强检查点干扰癌症疗法的性能
US20170231929A1 (en) * 2014-08-19 2017-08-17 National University Corporation Okayama University Method for enhancing immune cell function and method for assessing immune cell multifunctionality
AU2015327868A1 (en) 2014-10-03 2017-04-20 Novartis Ag Combination therapies
AU2015346295A1 (en) 2014-11-13 2017-05-25 The Johns Hopkins University Checkpoint blockade and microsatellite instability
WO2016173959A1 (en) * 2015-04-28 2016-11-03 Bayer Pharma Aktiengesellschaft Regorafenib for treating colorectal cancer
WO2017046746A1 (en) 2015-09-15 2017-03-23 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
US20190183972A1 (en) 2016-06-03 2019-06-20 Imclone Llc Combination of ramucirumab and pembrolizumab for the treatment of certain cancers
US10251888B2 (en) 2016-06-13 2019-04-09 Chemocentryx, Inc. Method of treating pancreatic cancer
WO2018219807A1 (en) 2017-06-02 2018-12-06 Bayer Aktiengesellschaft Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer
IL271009B2 (en) * 2017-06-05 2025-10-01 Janssen Biotech Inc Antibodies that specifically bind PD-1 and methods of use

Also Published As

Publication number Publication date
RS65488B9 (sr) 2024-09-30
US11951166B2 (en) 2024-04-09
CA3065125C (en) 2025-06-10
AU2018276273A1 (en) 2019-12-12
US20200155674A1 (en) 2020-05-21
CN117899212A (zh) 2024-04-19
EP4342542A3 (en) 2024-06-05
BR112019025478A2 (pt) 2020-06-23
RU2019143599A3 (enExample) 2021-09-10
JP7303122B2 (ja) 2023-07-04
LT3630112T (lt) 2024-05-10
CN110662540A (zh) 2020-01-07
US20220133888A1 (en) 2022-05-05
ES2978337T3 (es) 2024-09-10
EP3630112A1 (en) 2020-04-08
RU2019143599A (ru) 2021-07-09
JP2020521786A (ja) 2020-07-27
HUE066487T2 (hu) 2024-08-28
KR20200011971A (ko) 2020-02-04
AU2023282197A1 (en) 2024-01-04
PT3630112T (pt) 2024-04-23
JP7475402B2 (ja) 2024-04-26
IL317015A (en) 2025-01-01
MX2023001721A (es) 2023-02-22
AU2023282197B2 (en) 2025-06-26
IL270948B1 (en) 2025-03-01
KR20240091188A (ko) 2024-06-21
HRP20240551T1 (hr) 2024-07-05
KR102843438B1 (ko) 2025-08-06
DK3630112T3 (da) 2024-04-22
IL270948A (en) 2020-01-30
EP4342542A2 (en) 2024-03-27
EP3630112B9 (en) 2024-06-26
PE20242220A1 (es) 2024-11-19
CA3244313A1 (en) 2025-06-13
US11517622B2 (en) 2022-12-06
RS65488B1 (sr) 2024-05-31
AU2018276273B2 (en) 2023-12-21
US20200188372A1 (en) 2020-06-18
KR102673422B1 (ko) 2024-06-07
EP3630112B1 (en) 2024-01-31
IL270948B2 (en) 2025-07-01
FI3630112T3 (fi) 2024-05-02
BR112019025478A8 (pt) 2022-12-06
US20200179354A1 (en) 2020-06-11
CN117582495A (zh) 2024-02-23
CN110662540B (zh) 2024-01-26
WO2018219807A1 (en) 2018-12-06
CA3065125A1 (en) 2018-12-06
SI3630112T1 (sl) 2024-06-28
JP2022169780A (ja) 2022-11-09
PL3630112T3 (pl) 2024-07-01
JP2024096905A (ja) 2024-07-17

Similar Documents

Publication Publication Date Title
NZ770260A (en) Substituted heterocyclic inhibitors of ptpn11
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
MX391812B (es) Agonista fxr derivado de esteroides.
MX2019008207A (es) Métodos para tratar el cáncer con anticuerpos anti-pd-1.
BR112018003026A2 (pt) composições compreendendo um inibidor de pi3k e um inibidor de hdac
MX385428B (es) Combinación que comprende antagonista del receptor 4 de prostaglandina e2 (ep4) e inhibidor de punto de control inmunitario.
EA201991884A2 (ru) Ингибиторы g12c kras
PE20091655A1 (es) Farmaco para el cancer de higado
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
BR112017016817A2 (pt) derivados heterocíclicos formilados como inibidores de fgfr4
BR112013021566A2 (pt) composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula
EA201990678A1 (ru) Гетероарилкарбоксамидные соединения в качестве ингибиторов ripk2
UY37837A (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
MX2021010252A (es) Inhibidores del receptor de glucocorticoides.
JOP20190262B1 (ar) مثبطات بيرازول magl
JOP20190053A1 (ar) مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
PE20200859A1 (es) Combinacion farmaceutica que comprende regonafenib y nivolumab como anticancerigeno
MX388175B (es) Compuestos terapéuticos y métodos para utilizarlos
MX2016014946A (es) Derivados de carboxamida.
EA201891319A1 (ru) Соединения алкилдигидрохинолинсульфонамида
ZA202003281B (en) Heterocycle substituted pyridine derivative antifungal agents
MX371102B (es) Nuevos derivados de bencimidazol como agentes antihistaminicos.
EA201892539A1 (ru) Пиридинильные производные, фармацевтические композиции и их применение в качестве ингибиторов аос3
MX389261B (es) Alfa-amino esteres de derivado de hidroxipropiltiazolidin carboxamida, y formas de sales y polimorfos cristalinos de estos.
EA201991570A1 (ru) Амидные соединения и их применение